Patents Assigned to Helixmith Co., Ltd.
  • Patent number: 11975039
    Abstract: Disclosed are a pharmaceutical composition for treatment of attention deficit hyperactivity disorder and a food composition for alleviation of attention deficit hyperactivity disorder, each of which contains as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber, wherein the compositions containing as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber of the present disclosure inhibits the hyperactivity of glutamate receptors, which is known to be a cause of attention deficit hyperactivity disorder, alleviates clinical symptoms (attention decrease and hyperactivity) of child patients, and shows an improvement effect in fMRI examination results, and thus can be advantageously used as a medicine for attention deficit hyperactivity disorder or a food for alleviation of attention deficit hyperactivity disorder.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 7, 2024
    Assignee: HELIXMITH CO., LTD.
    Inventors: Miwon Son, Doo Suk Lee, Sunyoung Kim, In-Jeong Nam
  • Patent number: 11559555
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising as an active ingredient two or more mixed extracts selected from the group consisting of a Brassicae Semen extract, an Adenophorae Radix extract, a Lonicerae Folium extract and a Perillae Semen extract. A composition comprising mixed extracts of Brassicae Semen, Adenophorae Radix, Lonicerae Folium and Perillae Semen of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue, inhibits aging action and inflammation induced by inflammation-inducing substances such as fine dust, and has an excellent antioxidant effect. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 24, 2023
    Assignee: HELIXMITH CO., LTD.
    Inventors: Mi Won Son, Min Jung Bae, Won Woo Lee, Doo Suk Lee
  • Patent number: 11541097
    Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating respiratory diseases and a food composition for preventing or relieving respiratory diseases comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica as an active ingredient. A composition comprising a mixed extract of Dioscoreae Rhizoma, Taraxaci Herba and Schizonepetae Spica of the present disclosure has an advantage of preventing respiratory diseases and relieving the symptoms of respiratory diseases, restores damages in the lung tissue and has efficacy for inhibiting inflammation, oxidative stress and ageing reactions induced by fine dust. More particularly, the composition of the present disclosure increases the expression of a telomerase which extends the length of a telomere, and thus is expected to fundamentally treat degenerative respiratory diseases induced by fine dust unlike existing symptom alleviating agents.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 3, 2023
    Assignee: HELIXMITH CO., LTD.
    Inventors: Mi Won Son, Min Jung Bae, Won Woo Lee, Doo Suk Lee
  • Patent number: 11219667
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1? (SDF-1?); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1?. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1? or a polynucleotide codes a protein thereof.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 11, 2022
    Assignee: Helixmith Co., Ltd.
    Inventors: Jae-Gyun Jeong, Jung Hun Lee, Nayeon Lee
  • Publication number: 20210315958
    Abstract: Disclosed are a pharmaceutical composition for treatment of attention deficit hyperactivity disorder and a food composition for alleviation of attention deficit hyperactivity disorder, each of which contains as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber, wherein the compositions containing as an active ingredient a mixture extract of Longan Arillus, Salviae Miltiorrhizae Radix, Gastrodiae Rhizoma, and Liriopis seu Ophiopogonis Tuber of the present disclosure inhibits the hyperactivity of glutamate receptors, which is known to be a cause of attention deficit hyperactivity disorder, alleviates clinical symptoms (attention decrease and hyperactivity) of child patients, and shows an improvement effect in fMRI examination results, and thus can be advantageously used as a medicine for attention deficit hyperactivity disorder or a food for alleviation of attention deficit hyperactivity disorder.
    Type: Application
    Filed: May 9, 2019
    Publication date: October 14, 2021
    Applicants: HELIXMITH CO., LTD., HELIXMITH CO., LTD.
    Inventors: Miwon SON, Doo Suk LEE, Sunyoung KIM, In-Jeong NAM
  • Patent number: 10759841
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 1, 2020
    Assignee: Helixmith Co., Ltd.
    Inventors: Jong Mook Kim, Jae Gyun Jeong
  • Patent number: 10639351
    Abstract: The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: May 5, 2020
    Assignee: Helixmith Co., Ltd.
    Inventor: Jae Gyun Jeong